A Clinical Study To Evaluate The Performances of A Pulsed Electric Field Ablation Through Percutaneous Approach for Patients With Early-Stage Lung Cancer or Lung Oligometastatic Tumor.

by palligoelme@gmail.com | Sep 2, 2026 | Clinical Trials

​ Conditions: Lung Cancer (NSCLC) Interventions: Device: Pulsed Electric Field Ablation Sponsors: Energenx Medical LTD. Not yet recruiting Conditions: Lung Cancer (NSCLC) Interventions: Device: Pulsed Electric Field Ablation Sponsors: Energenx Medical LTD. Not yet...

Adaptation and Feasibility Testing of a Fatigue Intervention in Adults With TBI

by palligoelme@gmail.com | Sep 2, 2026 | Clinical Trials

​ Conditions: Traumatic Brain Injury Interventions: Behavioral: FACETS-TBI; Behavioral: Attention Control Sponsors: Craig Hospital Not yet recruiting Conditions: Traumatic Brain Injury Interventions: Behavioral: FACETS-TBI; Behavioral: Attention Control Sponsors:...

Investigating and Modelling the Natural History of Dengue in Hospitalised Patients to Improve Future Research

by palligoelme@gmail.com | Sep 2, 2026 | Clinical Trials

​ Conditions: Dengue Sponsors: Liverpool School of Tropical Medicine; Nagasaki University; Pasteur Institute, Nha Trang Not yet recruiting Conditions: Dengue Sponsors: Liverpool School of Tropical Medicine; Nagasaki University; Pasteur Institute, Nha Trang Not yet...

[Trial of device that is not approved or cleared by the U.S. FDA]

by palligoelme@gmail.com | Sep 1, 2026 | Clinical Trials

​ Sponsors: [Redacted] Withheld Sponsors: [Redacted] Withheld 

Evaluate the Efficacy and Safety of CTO0308 in Pediatric Patients With Myopia

by palligoelme@gmail.com | Sep 1, 2026 | Clinical Trials

​ Conditions: Myopia Interventions: Drug: CTO0308; Drug: Vehicle (Placebo solution) Sponsors: Taejoon Pharmaceutical Co., Ltd. Active, not recruiting Conditions: Myopia Interventions: Drug: CTO0308; Drug: Vehicle (Placebo solution) Sponsors: Taejoon Pharmaceutical...

Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1

by palligoelme@gmail.com | Sep 1, 2026 | Clinical Trials

​ Conditions: Ovarian Cancer Interventions: Drug: INCB123667; Drug: Bevacizumab; Drug: Placebo Sponsors: Incyte Corporation Not yet recruiting Conditions: Ovarian Cancer Interventions: Drug: INCB123667; Drug: Bevacizumab; Drug: Placebo Sponsors: Incyte Corporation Not...